BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21357681)

  • 1. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
    Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
    Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
    Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
    Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
    Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
    J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
    Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
    J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
    Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
    J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
    Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK
    Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
    Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
    Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis.
    Fujisawa T; Joshi B; Nakajima A; Puri RK
    Cancer Res; 2009 Nov; 69(22):8678-85. PubMed ID: 19887609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
    Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
    Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
    Leclercq S; Gueugnon F; Boutin B; Guillot F; Blanquart C; Rogel A; Padieu M; Pouliquen D; Fonteneau JF; Grégoire M
    Eur Respir J; 2011 Nov; 38(5):1105-16. PubMed ID: 21540307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning of the chicken interleukin-13 receptor alpha 2 gene and production of a specific monoclonal antibody.
    Miyoshi M; Horiuchi H; Fukushima Y; Matsuda H; Furusawa S
    Dev Comp Immunol; 2007; 31(4):394-406. PubMed ID: 16926048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
    Inamoto T; Yamada T; Ohnuma K; Kina S; Takahashi N; Yamochi T; Inamoto S; Katsuoka Y; Hosono O; Tanaka H; Dang NH; Morimoto C
    Clin Cancer Res; 2007 Jul; 13(14):4191-200. PubMed ID: 17634548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo.
    Inami K; Abe M; Takeda K; Hagiwara Y; Maeda M; Segawa T; Suyama M; Watanabe S; Hino O
    Cancer Sci; 2010 Apr; 101(4):969-74. PubMed ID: 20100205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2.
    Kasaian MT; Raible D; Marquette K; Cook TA; Zhou S; Tan XY; Tchistiakova L
    J Immunol; 2011 Jul; 187(1):561-9. PubMed ID: 21622864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo characterisation of anti-murine IL-13 antibodies recognising distinct functional epitopes.
    Berry LM; Adams R; Airey M; Bracher MG; Bourne T; Carrington B; Cross AS; Davies GC; Finney HM; Foulkes R; Gozzard N; Griffin RA; Hailu H; Lamour SD; Lawson AD; Lightwood DJ; McKnight AJ; O'Dowd VL; Oxbrow AK; Popplewell AG; Shaw S; Stephens PE; Sweeney B; Tomlinson KL; Uhe C; Palframan RT
    Int Immunopharmacol; 2009 Feb; 9(2):201-6. PubMed ID: 19041426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
    Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
    Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
    Jackaman C; Nelson DJ
    Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.
    Bender CM; Pao MM; Jones PA
    Cancer Res; 1998 Jan; 58(1):95-101. PubMed ID: 9426064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
    Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
    Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.